Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Abeona Therapeutics, Inc.
483
•Abeona Therapeutics, Inc.•March 1, 2024

Abeona Therapeutics, Inc. – FDA 483, Mar 1, 2024

Record Details

An FDA inspection conducted at Abeona Therapeutics Inc. from February 19 to March 1, 2024, identified critical deficiencies in their manufacturing and quality control systems. Issued under Section 704(b) of the Federal Food, Drug and Cosmetic Act, the observations highlight concerns regarding the company's adherence to Good Manufacturing Practices for cell and gene therapy products. Main violations include inadequate controls over aseptic manufacturing processes, such as insufficient validation of media, components, and bioburden limits, compromising sterility assurance for the final product. The firm also failed to adequately control the quality of media and reagents, lacking proper sterility, endotoxin, and identity testing, and without validated expiry dates. Quality Assurance demonstrated inefficient management of deviations, leading to delayed investigations, inadequate risk assessments, and the release of product lots with out-of-specification results for clinical use without proper justification or confirmed root causes. Retesting procedures were unclear, permitting multiple retests without identifying underlying issues. Lastly, disinfectant efficacy studies were deficient, failing to qualify primary disinfectants or evaluate facility isolates. Abeona Therapeutics is required to promptly address these observations by implementing comprehensive corrective and preventative actions to ensure product quality and patient safety.

Company
Abeona Therapeutics, Inc.
Inspection date
March 1, 2024
Product type
biologics
Office
Baltimore District Office
People
  • Alyssa N. Kitchel
  • Min-Shan-Ma Liu
  • Alyssa Sweeney
  • Christine Harman
  • Lawrence R. Deyton (Professor of Medicine)
View Company Profile

ID · 97434be4-98d1-416e-91bb-18f789c3b89f

Other documents for Abeona Therapeutics, Inc.
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Abeona Therapeutics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.